Charles Rosier - | CrunchBase
charles rosier (Crunchbase) was offered a job at Goldman Sachs in 1999. He became their Managing Director. The year 1996 marked his first step towards his future, gaining his first appointment at Lehman Brothers. Eventually, he became the manager of their Debt Capital Market Division, having moved to UBS Warburg in 1997. charles rosier was accountable for the French-speaking markets of France, Belgium, as well as Quebec at UBS Warburg.
Charles Rosier started his career at Lehman Brothers in 1996 prior to joining the incredible UBS Warburg Investment Bank. Charles Rosier was able to establish his profession right after obtaining a degree at ESCP Europe. His name became big in the market because he was able to hold varied positions throughout his career.
Culture and Music Projects
His love for music and culture paved the way to helping a French female musician. Charles Rosier has always had a love for music and singing. He admires French culture, which shows in how much he loves movies. Several charitable and cultural activities are supported by Charles Rosier. This is not surprising because he has shown support to a French artist and a Silver Lion-winning movie.
Positions Charles Rosier Held
From 1997 to 2009, Charles Rosier worked as the Debt Capital Manager at SBC Warburg. He also became a smart investment banker at Lehman Brothers, which marked the launching of his profession. He put in place five business rules (Customer Focus, Global Thinking Presence, Long Term View, Meritocracy and Partnership and World-Class Governance) at BTG Pactual. Charles Rosier was an active partner at BTG Pactual, an investment bank in Latin America.
Charles Rosier and His Healthcare Advocacies
When Baulieu and his co-workers were facing financial problems on developing a new drug, he willingly financed them. Charles Rosier’s very first healthcare project was the Mapreg Drug project. He invested capital in Mapreg, a Paris-based laboratory that was in the business of researching about depression, strokes and other severe issues. Charles Rosier was the project’s major investor. A drug treatment for strokes that can cause spinal cord injury was being tested.